CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
RAD001drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00516165
NCT00516165Phase 2Completed
CompareCT.gov

A Phase I/II Study of RAD001 in Advanced Hepatocellular Carcinoma

Massachusetts General Hospital·interventional·Posted Aug 15, 2007·Updated Feb 7, 2017

In Brief

A Phase 2 clinical trial evaluating RAD001 for Hepatocellular Carcinoma. Completed, enrolled 28 participants across 3 sites.

Detailed Summary

Laboratory studies have shown that RAD001 can prevent cells from multiplying. Consequently, the study drug is being tested in medical conditions in which excessive cell multiplication (as in cancer) needs to be stopped. The main purpose of this research study is to find the highest dose of RAD001 that can be given safely (without causing severe side effects) and to learn the effects (good or bad) RAD001 has on participants with liver cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesUnited States
CollaboratorsDana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Novartis

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2007
Enrollment StartAug 1, 2007
Primary CompletionJan 1, 2010
Study CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 18.9 years ago

Interventions

RAD001drug

Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days